Product Profiles

Article

Product Profiles

One-piece aspheric IOL with blue light filter

The IOL is constructed with a dense polymer network-ensuring long-term stability. The 360° sharp edges prevent epithelial cells from moving into the optic area, thus stopping early posterior capsule opacification (PCO). The haptic surface reduces haptic stickiness and makes the IOL easy to handle.

Fundus illumination

The system comes complete with a Photoxguard system. This touch-screen system includes individual user profiles and continuously monitors the emitted light. Photoxguard also warns the surgeon of any phototoxicity dangers. Surgical procedures can be completed at close proximity to the retina due to the increased safety features.

For more information please visit http://www.geuder.com/

Diffractive trifocal IOL

The IOL consists of a combination of two diffractive structures that are adjusted to offer a +3.5 D addition for near vision and another +1.75 D addition for intermediate vision. According to the company, the fact that this IOL reduces the loss of light energy results in a significantly improved performance for intermediate vision while also maintaining the performance at distance and near.

For more information please visit http://www.physiol.be/

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.